Moody's: Biosimilars a growing challenge for biotech drugs

8 October 2018

Competition from manufacturers of biosimilar drugs, or follow-on versions of complex biotech drugs, is a rising threat for branded pharmaceutical companies, Moody's Investors Service says in a new report.

Branded drugmakers including Switzerland’s Roche (ROG: SIX), and the USA’s Amgen (Nasdaq: AMGN), AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ will see declining sales of some of their best-selling drugs over the next 12 to 18 months.

"Over the next year or so, as biosimilars gain traction globally, several branded pharmaceutical companies will face declining sales of important blockbuster drugs," says Michael Levesque, a Moody's senior vice president. "Biosimilars have seen strong uptake in Europe and this trend will accelerate as the biosimilar market there continues to develop, with more drugs approved and launched," he added.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK